231 related articles for article (PubMed ID: 23399957)
1. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.
Garon EB; Pietras RJ; Finn RS; Kamranpour N; Pitts S; Márquez-Garbán DC; Desai AJ; Dering J; Hosmer W; von Euw EM; Dubinett SM; Slamon DJ
J Thorac Oncol; 2013 Mar; 8(3):270-8. PubMed ID: 23399957
[TBL] [Abstract][Full Text] [Related]
2. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP
J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
[TBL] [Abstract][Full Text] [Related]
4. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
5. Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib.
Xu R; Shen H; Guo R; Sun J; Gao W; Shu Y
Biomed Pharmacother; 2012 Jul; 66(5):384-9. PubMed ID: 22560634
[TBL] [Abstract][Full Text] [Related]
6. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
[TBL] [Abstract][Full Text] [Related]
7. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
Morrison G; Fu X; Shea M; Nanda S; Giuliano M; Wang T; Klinowska T; Osborne CK; Rimawi MF; Schiff R
Breast Cancer Res Treat; 2014 Apr; 144(2):263-72. PubMed ID: 24554387
[TBL] [Abstract][Full Text] [Related]
9. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
[TBL] [Abstract][Full Text] [Related]
10. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands.
Hershberger PA; Vasquez AC; Kanterewicz B; Land S; Siegfried JM; Nichols M
Cancer Res; 2005 Feb; 65(4):1598-605. PubMed ID: 15735050
[TBL] [Abstract][Full Text] [Related]
11. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
12. Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib.
Ling YH; Li T; Perez-Soler R; Haigentz M
Cancer Chemother Pharmacol; 2009 Aug; 64(3):539-48. PubMed ID: 19130057
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
[TBL] [Abstract][Full Text] [Related]
14. ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations.
Wang Z; Li Z; Ding X; Shen Z; Liu Z; An T; Duan J; Zhong J; Wu M; Zhao J; Zhuo M; Wang Y; Wang S; Sun Y; Bai H; Wang J
Sci Rep; 2015 Jun; 5():11392. PubMed ID: 26096604
[TBL] [Abstract][Full Text] [Related]
15. Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression.
Shen H; Liu J; Wang R; Qian X; Xu R; Xu T; Li Q; Wang L; Shi Z; Zheng J; Chen Q; Shu Y
Biomed Pharmacother; 2014 Apr; 68(3):307-13. PubMed ID: 24268810
[TBL] [Abstract][Full Text] [Related]
16. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
17. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.
Okubo S; Kurebayashi J; Otsuki T; Yamamoto Y; Tanaka K; Sonoo H
Br J Cancer; 2004 Jan; 90(1):236-44. PubMed ID: 14710235
[TBL] [Abstract][Full Text] [Related]
18. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
Zou Y; Ling YH; Sironi J; Schwartz EL; Perez-Soler R; Piperdi B
J Thorac Oncol; 2013 Jun; 8(6):693-702. PubMed ID: 23575415
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptors, antiestrogens, and non-small cell lung cancer.
Bogush TA; Dudko EA; Beme AA; Bogush EA; Kim AI; Polotsky BE; Tjuljandin SA; Davydov MI
Biochemistry (Mosc); 2010 Dec; 75(12):1421-7. PubMed ID: 21314611
[TBL] [Abstract][Full Text] [Related]
20. Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines.
Sommer A; Hoffmann J; Lichtner RB; Schneider MR; Parczyk K
J Steroid Biochem Mol Biol; 2003 May; 85(1):33-47. PubMed ID: 12798355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
